BERKELEY HEIGHTS, N.J., November 27, 2002
-- Genta Incorporated (Nasdaq: GNTA - News) today announced the
appointment of Jerome E. Groopman, M.D., to the Company"s Board of
Directors. Dr. Groopman, who is Professor of Medicine and Chief of
Experimental Medicine at the Beth Israel Deaconess Medical Center
in Boston, also holds the Dina and Raphael Recanati Chair of
Medicine at Harvard.
Dr. Groopman has an extensive record of achievement
in basic and clinical research related to cancer, hematology, and
HIV infection. He has served on the Advisory Council to the
National Heart, Lung and Blood Institute (NHLBI) for AIDS-related
diseases. He was Chairman of the Advisory Committee to the Food and
Drug Administration (FDA) for Biological Response Modifiers. In
2000, Dr. Groopman was elected to the Institute of Medicine of the
National Academy of Sciences. Dr. Groopman also serves on many
scientific editorial boards and has authored has published more
than 150 scientific articles. Recently, he has written two books
related to the devastating personal impact of disease in people
afflicted with AIDS and cancer entitled, "The Measure of Our Days,"
and "Second Opinions: Stories of Intuition and Choice in the
Changing World of Medicine." Among other periodicals, he is a
frequent contributor to The New Yorker magazine, where he is staff
writer on medicine and biology. Dr. Groopman received B.A. and M.D.
degrees from Columbia University, completed internal medicine
residency at the Massachusetts General Hospital, and underwent
subspecialty fellowship training in hematology and oncology at UCLA
and the Dana Farber Cancer Institute.
"Dr. Groopman joins the Board at a pivotal time for
Genta. His expertise in research, clinical, and regulatory affairs
will make a critical contribution as we move toward the successful
commercialization of our leading anticancer compounds," stated Dr.
Raymond P. Warrell, Jr., Genta"s Chairman of the Board and Chief
Executive Officer. "Supporting Genta"s efforts in transforming
research programs into clinical options for cancer patients is an
exciting prospect for me," stated Dr. Groopman. "I look forward to
sharing my insights in key areas that will assist the impressive
leadership already assembled on the Genta Board."
